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cluded a number of prominent publicly available sets with both gene
expression and copy number data leading to a cohort of almost 500
men (Ross-Adams et al., 2015; Taylor et al., 2010; Grasso et al., 2012).
We also included a small landmark series of expression data




Big dataObtaining access to robust, well-annotated human genomic datasets
is an important step in demonstrating the relevance of experimental
ﬁndings and, often, in generating the hypotheses that led to those ex-
periments being conducted in the ﬁrst place. We recently published
data from the CamCaP Study Group which comprised two cohorts of
men with prostate cancer who had undergone prostatectomy in Cam-
bridge, UK and Stockholm, Sweden (Ross-Adams et al., 2015). We con-
sidered how we might best share our output with those who wish to
interrogate the data with their own ideas, gene lists and clinical ques-
tions.We recognised thatﬁnding, down-loading, pre-processing and as-
similating any suchdataset into a usable format is daunting andmay put
off many researchers. We also felt that interrogation tools generated to
date (e.g. cBioPortal) lack functionality as they either cover too many
organ types, or are limited in the extent, precision and tumour-site
speciﬁcity of their clinical annotation. We therefore determined to
produce an accessible web-based platform that would permit
straightforward interrogation of these datasets with individual
gene identiﬁers or gene sets. Furthermore, we decided to include ad-
ditional ‘publicly-accessible’ human prostate cancer sets in order tocAPP/.
mb).
. This is an open access article underincrease the number of samples available and provide a degree of vali-
dation of any observations made across independent cohorts. We in-
We plan to include additional studies in the app as well-annotated
datasets become publicly available.
An important ﬁnding in our recent study was that prostate cancer
could be divided into ﬁve distinct molecular subgroups based on strati-
ﬁcation with a small number of copy number features which were also
associated with RNA-expression change. These groups had different
clinical outcomes.Wewanted the app to allow researchers to determine
the mean RNA-expression level or copy number status of a single gene
or gene-set in prostates from men divided either according to clinical
categories (Gleason score, biochemical relapse status or tumour type)
or according to molecular subgroups. These subgroups could either be
pre-deﬁned molecular groups published in the relevant papers, or de
novo subgroups generated by hierarchical clustering based on an
uploaded geneset.
We searched for other web-tools that are already available for this
purpose. Although no such site exists for assessment of subgroup pat-
terns or combined expression and copy number proﬁles, the Memorial
Sloane Kettering Cancer Centre (MSKCC) and Michigan data (Table 1)
can be analysed as part of cBioPortal (cBioPortal for Cancer Genomics,
n.d.) along with the recently published prostate TCGA dataset
(Robinson et al., 2015).
Here we introduce the camcAPP (http://bioinformatics.cruk.cam.ac.
uk/apps/camcAPP/); a bespoke web interface to multiple prostate
cancer genomics datasets. The interface was created with Shiny
(https://www.rstudio.com/products/shiny/), and allows the non-
specialist Bioinformatician to create publication-ready ﬁgures and ta-
bles through an intuitive interface to the underlying computer code.
After selecting a dataset of interest, and uploading a list of genes, the
following analyses can be performed:
1) Boxplots and analysis of variance for expression of genes of interest
grouped by clinical group, sample type, Gleason grade of copy-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Summary of studies included in the camcAPP at initial release. Primary Tumours = tissue taken from radical prostatectomy specimens in men with conﬁrmed organ-conﬁned disease.
Advanced Tumours = tissue from channel transurethral resection of the prostate (chTURP) or prostatectomy in men with metastatic disease.
Dataset Paper Platform: gene expression Platform: copy number Primary tumours Advanced tumours Clinical covariates
Michigan 2005 Varambally et al. (2005)
GSE3325
Affymetrix U133 2.0 N/A 7 6 Sample Group
MSKCC 2010 Taylor et al. (2010)
GSE21032
Affymetrix Human 1.0 ST Agilent 244k 109 19 Gleason, Copy Number Cluster
Michigan 2012 Grasso et al. (2012)
GSE35988
Agilent Whole Human 44k Agilent 105k/244k 59 32 Sample Group
Stockholm 2015 Ross-Adams et al. (2015)
GSE70770
Illumina HT12 Affymetrix SNP 6.0 101 N/A iCluster, Sample Group
Cambridge 2015 Ross-Adams et al. (2015)
GSE70770
Illumina HT12 Illumina Omni 2.5 125 19 iCluster, Gleason, Sample Group
6 M.J. Dunning et al. / EBioMedicine 17 (2017) 5–6number cluster (N.B. not all covariates available for all data sets) (see
Supplementary Fig. 2).
2) A recursive partitioning-based survival analysis and Kaplan-Meier
plots on a gene-by-gene basis (Supplementary Fig. 3).
3) Pairwise-correlations of gene expression across whole studies and
within clinical subgroups.
4) Clustering andheatmaps of gene expression data,with options to in-
terrogate associations between clinical covariates and newly-
derived clusters (Supplementary Fig. 4).
5) Tabulating the number of copy-number ampliﬁcations and deletions
observed across whole studies or within a particular clinical covari-
ate, and making a heatmap of copy-number calls (Supplementary
Fig. 5) (Lalonde et al., 2014).
One of the challenges in constructing such a tool is delivering an out-
put format that is readily transferable to slides for presentations or
panels of a ﬁgure for publication. We recognise that this is, in part, a
matter of axis typesetting and plot conﬁguration but also of delivering
an output ﬁle which permits further adjustment of the ﬁgure in, for ex-
ample, Adobe Illustrator™. To this end, all plots can be exported as PDF
or PNG ﬁles with conﬁgurable dimensions. Furthermore, for those that
are well-versed in R, the code to produce a particular plot can be
downloaded and modiﬁed as required. A further challenge that we
seek to address with this interface is merging datasets for combined
analysis. We hope to offer this option in due course, as we include fur-
ther datasets that include samples analysed on compatible platforms.
Strategies to address the Big Data problem have focussed onmaking
the ever-increasing volume of genomic data accessible to scientists and
on opening up the possibility of engaging non-specialists (Keener,
2015). This approach embodies a responsible attitude to science both
in terms of patient input and ﬁnancial resource and we believe that
tools such as this are an important step to maximising the value of
these landmark studies.We take pleasure inmaking this platform avail-
able to the prostate cancer community bymeans of this ‘In Focus’ article
in EBioMedicine, a journal that we believe champions this responsible
approach to genomic data both in cancer genomics (Kerns et al., 2016)
and further aﬁeld (Taudien et al., 2016).
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Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2017.02.022. This includes a ‘manual’ for the
Shiny App which can also be downloaded from the app itself.
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